Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04111185 · ClinicalTrials.gov registry record · NA

Daxor - Blood Volume Analysis

A NA study of Heart Failure and Congestive Heart Failure, sponsored by Duke University.

Completed
Registry status
NA
Development phase
31
Enrollment target
1
Study location

NCT04111185: Completed NA study of Heart Failure and Congestive Heart Failure, sponsored by Duke University.

NCT04111185 is a NA study of Heart Failure and Congestive Heart Failure that has completed, run by Duke University. The registered enrollment target is 31 participants, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04111185, a NA study of Heart Failure and Congestive Heart Failure, has completed, sponsored by Duke University.

COMPLETED
Registry status
NA
Development phase
31 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to better understand blood volume status and whether knowledge of it can change and improve heart failure care.

Interventions

  • DEVICE Receive Blood Volume Analysis Guided Treatment

Study Locations (1)

North Carolina

  • Duke University - Durham

Trial Details

FieldValue
Enrollment Target 31 participants
Start Date 2020-07-16
Est. Completion 2021-09-23
Phase NA
Duke University

1,725 total trials

What the finished NCT04111185 record still lists

NCT04111185 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (98% lower).

The record links to 2 conditions, with Heart Failure appearing as the primary indexed condition, and to 1 intervention - of which Receive Blood Volume Analysis Guided Treatment is the first listed.

NCT04111185 reports a single indexed study location in North Carolina.

Frequently Asked Questions

What is clinical trial NCT04111185 about?

NCT04111185 is a clinical study titled "Daxor - Blood Volume Analysis". The purpose of this study is to better understand blood volume status and whether knowledge of it can change and improve heart failure care.

What is the current status of trial NCT04111185?

This trial is currently completed. It is a NA study. The enrollment target is 31 participants. The study started on 2020-07-16. Estimated completion is 2021-09-23.

What conditions does trial NCT04111185 study?

This clinical trial studies the following conditions: Heart Failure, Congestive Heart Failure.

What interventions are being tested in trial NCT04111185?

The interventions under investigation include: Receive Blood Volume Analysis Guided Treatment (DEVICE).

Who is sponsoring clinical trial NCT04111185?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04111185 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Heart Failure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04111185's enrollment target sits among peer trials

31 319th of 397 higher than 77 of 397 other Heart Failure trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02932618 · 31 participants · Phase 3

    A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)

  • NCT03482297 · 31 participants · Phase 1

    Automated Abdominal Binder for Orthostatic Hypotension

  • NCT04016389 · 31 participants · NA

    FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery

  • NCT04211675 · 31 participants · Phase 1

    NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04111185, the US trial registry maintained by the National Library of Medicine. NCT04111185 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.